The cholecystokinin-2 receptor (CCK-2R), which is overexpressed in a variety of cancer types, such as MTC (92%), small cell lung cancer (57%), astrocytoma (65%) and stromal ovarian cancer (100%), was reported to be a promising target for RLT [14–17]. This evidence concerns the gene CCKBR and medullary thyroid gland carcinoma.